Animal models are essential for understanding the molecular causes for cancers and assessing potential therapeutic approaches. The facility's mission is to maximize the scientific benefits of animal experimentation, while maintaining an emphasis on animal welfare. Both of these efforts have been successful. From the animal welfare standpoint. Animal Resources has been AAALAC accredited since 1988, with the most recent renewal completed in March 2009. Scientifically, the facility has been critical to the success of the Cancer Center, supporting a wide variety of studies, which resulted in over 200 publications in the past funding period. Animal Resources occupies 12,800 sq. ft. of space, almost 10,000 of which belong to the centralized breeding facility, which has been expanded and upgraded to all ventilated caging. For active experimentation, mice are transferred to a facility in the building next door (1,740 sq. ft.). The Resource currently operates at 76% of its current capacity of 9,400 cages, housing more than 480 genetically altered lines of mice. Services include: 1] husbandry 2] breeding colony maintenance (the $0.64/cage per diem rate includes husbandry, breeding, weaning, ear notching, tail sampling) 3] transgenic/knockout mouse facility, 4] in vivo imaging and analysis facility, and 5] technical support (e.g., blood collection, injections, drug administration, tumor measurements, anesthesia, surgeries, post-op care). Operating costs of Resource services are recovered largely on a charge-back basis from facility users, with capital equipment, equipment maintenance, and construction funds provided from Institute support. The current funding period has seen an increase in the use of vivarium resources to study cancer-related phenomena. The Facility offers several standardized models for studying tumor formation and metastasis, and will continue to expand this effort. The In Vivo imaging and Analysis Facility, initiated in the last funding period, supports bioluminescent and fluorescent imaging (Xenogen IVIS200), ultrasound imaging (Visual Sonics Vevo770), along with hematology and serum analysis. The Resource stocks a panel of well characterized standard and luciferase-labeled tumor cell lines, to expand investigators'ability to quantify and characterize tumor progression. Additional imaging instrumentation, such as intravital microscopy and microPET will be evaluated for future acquisition. In 2008, 96% of the Resource users were Cancer Center members, with a total of 40 Cancer Center investigators from all four Programs utilizing the Resource. $124,455 in CCSG support is requested in the first year, representing 4.6% of the total estimated annual operating budget.

Public Health Relevance

Animal models are essenfial for understanding cancer, both for experimentally understanding underlying genetic participants in cancer progression in transgenic and knockout models, and for studying features of tumor development and progression features where in vivo analysis is essential, such as angiogenesis, tumor/ stromal interactions, tumor growth, metastasis, and in vivo efficacy of therapeufic compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA030199-32
Application #
8473821
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
32
Fiscal Year
2013
Total Cost
$205,537
Indirect Cost
$100,414
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Lechtenberg, Bernhard C; Rajput, Akhil; Sanishvili, Ruslan et al. (2016) Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation. Nature 529:546-50
Zhong, Zhenyu; Umemura, Atsushi; Sanchez-Lopez, Elsa et al. (2016) NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell 164:896-910
Olson, Erika J; Lechtenberg, Bernhard C; Zhao, Chunxia et al. (2016) Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability. ACS Med Chem Lett 7:841-6
Tinoco, Roberto; Carrette, Florent; Barraza, Monique L et al. (2016) PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity 44:1190-203
Zhao, Wei; Mazar, Joseph; Lee, Bongyong et al. (2016) The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes. J Invest Dermatol 136:819-28
Singec, Ilyas; Crain, Andrew M; Hou, Junjie et al. (2016) Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic Profiling. Stem Cell Reports 7:527-42
McQuary, Philip R; Liao, Chen-Yu; Chang, Jessica T et al. (2016) C. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan Extension. Cell Rep 14:2059-67
Moscat, Jorge; Karin, Michael; Diaz-Meco, Maria T (2016) p62 in Cancer: Signaling Adaptor Beyond Autophagy. Cell 167:606-609
Miletic, Ana V; Jellusova, Julia; Cato, Matthew H et al. (2016) Essential Role for Survivin in the Proliferative Expansion of Progenitor and Mature B Cells. J Immunol 196:2195-204
Koh, Mei Yee; Gagea, Mihai; Sargis, Timothy et al. (2016) A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology 63:1576-91

Showing the most recent 10 out of 425 publications